Alumis (NASDAQ:ALMS) Reaches New 1-Year High on Insider Buying Activity

Alumis Inc. (NASDAQ:ALMS)’s stock price hit a new 52-week high during mid-day trading on Tuesday following insider buying activity. The company traded as high as $22.39 and last traded at $21.98, with a volume of 1607602 shares traded. The stock had previously closed at $21.09.

Specifically, major shareholder Foresite Labs, Llc purchased 411,764 shares of the stock in a transaction dated Thursday, January 8th. The shares were purchased at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the acquisition, the insider directly owned 5,702,536 shares in the company, valued at $96,943,112. This trade represents a 7.78% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director James B. Tananbaum bought 411,764 shares of the stock in a transaction on Thursday, January 8th. The shares were bought at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the purchase, the director directly owned 5,702,536 shares in the company, valued at approximately $96,943,112. This trade represents a 7.78% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In related news, major shareholder Foresite Capital Management Vi bought 411,764 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The shares were bought at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the acquisition, the insider owned 5,702,536 shares of the company’s stock, valued at $96,943,112. This trade represents a 7.78% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Analyst Ratings Changes

ALMS has been the topic of several research analyst reports. Guggenheim increased their price target on Alumis from $18.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Oppenheimer reissued an “outperform” rating and issued a $50.00 target price on shares of Alumis in a research report on Tuesday, January 6th. Wells Fargo & Company boosted their price target on Alumis from $17.00 to $39.00 and gave the company an “overweight” rating in a research note on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alumis in a research note on Monday, December 29th. Finally, Citigroup restated an “outperform” rating on shares of Alumis in a research report on Tuesday, January 6th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $37.67.

Key Stories Impacting Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Major insider/affiliated fund bought 411,764 shares (~$7.0M) at $17.00 per share, increasing their stake by ~7.8% to 5,702,536 shares — a direct vote of confidence from Director James B. Tananbaum / Foresite-affiliated entities. Filing: SEC Filing
• Positive Sentiment: Multiple news outlets reported the purchase, amplifying market attention and likely contributing to today’s volume spike and upward price pressure. (Example coverage) Investing.com article
• Positive Sentiment: Recent analyst activity: several firms (UBS, Oppenheimer, Guggenheim, Wells Fargo, Citi) have issued Outperform/Buy or raised price targets in early January, lifting consensus sentiment and supporting higher valuations. (Market commentary) MarketBeat coverage
• Neutral Sentiment: Short interest data in the alert is effectively zero/flat and shows no immediate squeeze signal; days-to-cover reported as 0.0, so short activity is not currently driving price action.
• Neutral Sentiment: Institutional holders (Vanguard, Samsara, Orbimed, Trium) have recently adjusted stakes — shows growing institutional interest but also concentration among a few large holders. Institutional holdings
• Negative Sentiment: Fundamental risk remains: Alumis missed Q3 EPS and revenue estimates in its last report (Nov. 13), underscoring execution and near-term cash/revenue risk despite optimism on pipeline. Earnings detail

Alumis Stock Performance

The company has a market capitalization of $2.31 billion, a PE ratio of -5.46 and a beta of -2.09. The company’s fifty day moving average is $9.54 and its 200-day moving average is $6.08.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The business had revenue of $2.07 million for the quarter, compared to analyst estimates of $3.14 million. On average, sell-side analysts expect that Alumis Inc. will post -8.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Alumis

Institutional investors and hedge funds have recently bought and sold shares of the business. Stoneridge Investment Partners LLC lifted its position in shares of Alumis by 8.1% in the third quarter. Stoneridge Investment Partners LLC now owns 29,535 shares of the company’s stock valued at $118,000 after acquiring an additional 2,210 shares in the last quarter. Rhumbline Advisers raised its stake in Alumis by 21.7% during the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after purchasing an additional 2,949 shares during the period. Russell Investments Group Ltd. lifted its holdings in Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after purchasing an additional 4,894 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Alumis by 64.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock worth $77,000 after purchasing an additional 4,926 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in Alumis by 104.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,770 shares of the company’s stock valued at $47,000 after buying an additional 6,027 shares in the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.